Exendin-4 derivatives as selective glucagon receptor agonists

Patent metadata

Field	Value
Publication number	US-9932381-B2
Application number	US-201514738261-A
Country	US
Kind code	B2
Filing date	Jun 12, 2015
Priority date	Jun 18, 2014
Publication date	Apr 3, 2018
Grant date	Apr 3, 2018

Abstract

The present invention relates to glucagon receptor agonists and their medical use, for example in the treatment of severe hypoglycemia.

First claim

The invention claimed is:

1. A peptidic compound having the formula (I):
Tza-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-Lys-Gln-X14-Glu-Ser-Arg-Arg-Ala-Gln-X21-Phe-Ile-Glu-Trp-Leu-Leu-Ala-X29-Gly-Pro-Glu-Ser-Gly-Ala-Pro-Pro-Pro-Ser-R 1   (I)

wherein,
X10 represents an amino acid residue selected from Tyr, Leu, Val, Ile, Phe, Phenylglycine, 1-Naphthylalanine, 2-Fluorophenylalanine, Cyclohexylglycine and tert-Leucine;
X14 represents an amino acid residue selected from Leu and Nle;
X21 represents an amino acid residue selected from Asp and Glu;
X29 represents an amino acid residue selected from Gly and Thr; and
R 1 represents OH or NH 2 ;

or a salt or solvate thereof.

2. The peptidic compound of claim 1 , wherein R 1 represents OH.

3. The peptidic compound of claim 1 , wherein,
X10 represents Leu;
X14 represents an amino acid residue selected from Leu and Nle;
X21 represents an amino acid residue selected from Asp and Glu;
X29 represents an amino acid residue selected from Gly and Thr; and
R 1 represents OH;

or a salt or solvate thereof.

4. The peptidic compound of claim 1 , wherein,
X10 represents Tyr;
X14 represents an amino acid residue selected from Leu and Nle;
X21 represents Glu;
X29 represents an amino acid residue selected from Gly and Thr; and
R 1 represents OH;

or a salt or solvate thereof.

5. The peptidic compound of claim 1 , wherein,
X10 represents 1-Naphthylalanine;
X14 represents an amino acid residue selected from Leu and Nle;
X21 represents an amino acid residue selected from Asp and Glu;
X29 represents Thr; and
R 1 represents OH;

or a salt or solvate thereof.

6. The peptidic compound of claim 1 , wherein,
X10 represents Cyclohexylglycine;
X14 represents an amino acid residue selected from Leu and Nle;
X21 represents an amino acid residue selected from Asp and Glu;
X29 represents Thr; and
R 1 represents OH;

or a salt or solvate thereof.

7. The peptidic compound of claim 1 , wherein,
X10 represents an amino acid residue selected from Tyr, Leu, Val, Ile, Phenylglycine, 1-Naphthylalanine, 2-Fluorophenylalanine and Cyclohexylglycine;
X14 represents Leu;
X21 represents an amino acid residue selected from Asp and Glu;
X29 represents an amino acid residue selected from Gly and Thr; and
R 1 represents OH;

or a salt or solvate thereof.

8. The peptidic compound of claim 1 , wherein,
X10 represents an amino acid residue selected from Tyr, Leu, Ile, Phe, 1-Naphthylalanine, Cyclohexylglycine and tert-Leucine;
X14 represents Nle;
X21 represents an amino acid residue selected from Asp and Glu;
X29 represents Thr; and
R 1 represents OH;

or a salt or solvate thereof.

9. The peptidic compound of claim 1 , wherein,
X10 represents an amino acid residue selected from Leu, Phe, 1-Naphthylalanine, 2-Fluorophenylalanine and Cyclohexylglycine;
X14 represents an amino acid residue selected from Leu and Nle;
X21 represents Asp;
X29 represents Thr; and
R 1 represents OH;

or a salt or solvate thereof.

10. The peptidic compound of claim 1 , wherein,
X10 represents an amino acid residue selected from Tyr, Leu, Val, Ile, Phenylglycine, 1-Naphthylalanine, Cyclohexylglycine and tert-Leucine;
X14 represents an amino acid residue selected from Leu and Nle;
X21 represents Glu;
X29 represents an amino acid residue selected from Gly and Thr; and
R 1 represents OH;

or a salt or solvate thereof.

11. The peptidic compound of claim 1 , wherein,
X10 represents an amino acid residue selected from Tyr, Leu, Val, Ile, Phe, Phenylglycine, 1-Naphthylalanine, 2-Fluorophenylalanine, Cyclohexylglycine and tert-Leucine;
X14 represents an amino acid residue selected from Leu and Nle;
X21 represents an amino acid residue selected from Asp and Glu;
X29 represents Thr; and
R 1 represents OH;

or a salt or solvate thereof.

12. The peptidic compound of claim 1 , wherein,
X10 represents an amino acid residue selected from Tyr, Leu and Val;
X14 represents Leu;
X21 represents Glu;
X29 represents Gly; and
R 1 represents OH;

or a salt or solvate thereof.

13. The peptidic compound of claim 1 , wherein the peptidic compound is selected from the compounds of SEQ ID NO: 3-25 or a salt or solvate thereof.

14. The peptidic compound of claim 1 , wherein the peptidic compound is selected from the compounds of SEQ ID NO:3, 5, 6, 9, 15, 20, 23, 24 and 25 or a salt or solvate thereof.

15. A pharmaceutical composition comprising the peptidic compound of claim 1 and at least one pharmaceutically acceptable carrier.

16. A method for treating hypoglycemia or type 2 diabetes mellitus in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of at least one peptidic compound of claim 1 .

17. A pharmaceutical composition comprising at least one peptidic compound of claim 1 or a physiologically acceptable salt or solvent thereof.

18. A method for treating hypoglycemia in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of at least one peptidic compound of claim 1 .

19. The method of claim 18 , wherein the at least one peptidic compound and the at least one other compound are administered simultaneously, separately, or sequentially.

20. The method of claim 18 , wherein the at least one peptidic compound is administered parenterally.

21. A method for treating hypoglycemia in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of at least one peptidic compound of claim 1 and a therapeutically effective amount of at least one other compound useful for treating hypoglycemia.

Assignees

• Sanofi Sa

Inventors

• Haack Torsten
• Stengelin Siegfried
• Evers Andreas
• Wagner Michael
• Henkel Bernd

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P5/48

  of the pancreatic hormones · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/08

  for glucose homeostasis (pancreatic hormones A61P5/48) · CPC title

• A61P39/02

  Antidotes · CPC title